CapsoVision, Inc

Overview

Compare with Hyperfine, Inc., ESCALON MEDICAL CORP or QT IMAGING HOLDINGS, INC., or pick any stock.

• TickerCV on Nasdaq²
• IndustryElectromedical & Electrotherapeutic Apparatus²
• HeadquartersSaratoga, United States²
• Incorporated inDE³
• Business address18805 Cox Avenue Suite 250, Saratoga, Ca 95070³
• Filer category, Emerging growth company³
• Legal formCorporation²
• LEI529900I9VO18RX33ME31²
• StatusActive²
• LEI statusIssued and current²
• Registered addressc/o NATIONAL REGISTERED AGENTS, INC., 1209 ORANGE STREET, 19801 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 4008445²

See how the biggest companies compare on our leaderboards

We are a global commercial-stage medical technology company focused on creating diagnostic and screening products to identify abnormalities of the GI tract. We develop advanced imaging and AI technologies in creating such products while maximizing the flexibility, convenience, profitability, and safety of patient care. We are a Delaware company, incorporated in 2005. Our corporate headquarters is located in Saratoga, California.⁴ From its latest annual report

Corporate structure

CapsoVision, Inc sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CapsoVision, Inc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Inventory

Properties, in its own words

Our principal office is located at 18805 Cox Avenue, Suite 250, Saratoga, California 95070, where we lease 14,058 square feet of space to house our principal office, manufacturing and warehouse facilities to support our business operations and clinical trial supply. This lease will expire in 2027, subject to our option to an additional three-year term. We lease two office facilities in Taiwan, where a small group of our employees are stationed, pursuant to two lease agreements: (i) a lease agreement for 12 months that commenced on February 15, 2025 and was renewed on the original expiration date of February 14, 2026 for another year until February 14, 2027, and (ii) a lease agreement for 12 months which commenced on May 16, 2025 and will expire on May 15, 2026.

Our existing facilities will continue to support our research and development, finance, marketing, and administrative teams. We believe that our facilities are adequate to support our expansion through the end of the facilities’ lease periods. We believe that suitable additional or alternative space would be available in the future as required on commercially reasonable terms.

Item 2 of the 10-K filed Mar 26, 2026.⁴

Leadership

Who has led CapsoVision, Inc, and when. Pick a name to see everywhere that person has worked.

• Chief financial officerKevin Michael Lundquist Jul 1, 2025 to now⁸

Named in SEC Form D filings

People the company listed in its private-offering notices.

• DirectorEli Huai Harari named Jul 23, 2024¹⁹
• DirectorHeidi Huai Chung named Jul 23, 2024¹⁹
• DirectorHoward Huai Lee named Jul 23, 2024¹⁹
• DirectorM.L. Huai Chen named Jul 23, 2024¹⁹
• DirectorPatty Huai Kuo named Jul 23, 2024¹⁹
• DirectorPen-Jung Huai Tseng named Jul 23, 2024¹⁹

Former names

• Capso Vision IncOct 10, 2006 to Feb 21, 2014³

Timeline

1. Sep 28, 20268-K Other events²⁰
2. Sep 18, 20268-K Entered a material agreement²¹
3. Aug 18, 20268-K Other events²²
4. Aug 13, 20268-K Entered a material agreement; Results of operations²³
5. Jul 2, 20268-K Executive or director change; Regulation FD disclosure²⁴
6. Jun 12, 20268-K Shareholder vote²⁵
7. May 14, 20268-K Results of operations²⁶
8. Mar 26, 20268-K Results of operations²⁷
9. Mar 20, 20268-K Entered a material agreement; Results of operations; Unregistered sale of shares²⁸
10. Mar 13, 20268-K Entered a material agreement²⁹
11. Dec 29, 20258-K Other events³⁰
12. Nov 13, 20258-K Results of operations³¹
13. Aug 1, 2005Founded CapsoVision, Inc is founded²

Calendar

Coming up

1. Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.17) a share, on Nov 13, 2025.³²

When it reported results

1. Aug 13, 2026Reported quarterly or annual results²³
2. May 14, 2026Reported quarterly or annual results²⁶
3. Mar 26, 2026Reported quarterly or annual results²⁷
4. Mar 20, 2026Reported quarterly or annual results²⁸
5. Nov 13, 2025Reported quarterly or annual results³¹
6. Aug 14, 2025Reported quarterly or annual results³³

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

125 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 19 major events, 61 insider forms, 7 large holders, 3 private raises, 30 other. The latest 20:

1. Sep 28, 20268-K EDGAR
2. Sep 23, 20264/A PRIMARY DOCUMENT EDGAR
3. Sep 23, 20264/A PRIMARY DOCUMENT EDGAR
4. Sep 23, 20264 PRIMARY DOCUMENT EDGAR
5. Sep 18, 20264 PRIMARY DOCUMENT EDGAR
6. Sep 18, 2026424B5 EDGAR
7. Sep 18, 20268-K EDGAR
8. Aug 21, 2026EFFECT EDGAR
9. Aug 21, 2026424B5 EDGAR
10. Aug 18, 20268-K EDGAR
11. Aug 13, 2026S-3 EDGAR
12. Aug 13, 202610-Q EDGAR
13. Aug 13, 20268-K EDGAR
14. Jul 21, 20264 PRIMARY DOCUMENT EDGAR
15. Jul 10, 20264 PRIMARY DOCUMENT EDGAR
16. Jul 7, 20264 PRIMARY DOCUMENT EDGAR
17. Jul 2, 20264 EDGAR
18. Jul 2, 20263 EDGAR
19. Jul 2, 20268-K EDGAR
20. Jul 1, 20264 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 7 buys and 1 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Eli HarariSCHEDULE 13G/A, 2 filings Oct 14, 2025 to May 6, 2026³⁴
• Ching Hang ShenSCHEDULE 13G/A, 2 filings Dec 22, 2025 to Apr 15, 2026³⁵
• CID Greater China Venture Capital Fund III, L.P.SCHEDULE 13G/A, 2 filings Oct 29, 2025 to Apr 7, 2026³⁶
• KIOXIA CorpSCHEDULE 13G, 1 filing Nov 12, 2025³⁷

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Money raised

Private offerings the company reported to the SEC on Form D.

1. Nov 21, 2019Raised $64.8 million in a private offering of equity Form D: $64.8 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 50. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How CapsoVision, Inc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARCapsoVision, Inc¹
• CIK0001378325
• Employer ID (EIN)20-3369494⁴
• Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company⁴
• Incorporated inDelaware⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)3845 Electromedical & Electrotherapeutic Apparatus¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address18805 Cox Avenue Suite 250, Saratoga, CA 95070¹
• Phone(408) 370-4790¹
• Shares outstanding50,046,913 as of Aug 12, 2026⁷
• Public float$0 as of Jun 30, 2025⁵
• AuditorBaker Tilly US, LLP, Santa Clara, California PCAOB ID 23; no auditor attestation of internal control over financial reporting⁴
• On EDGAR sinceOct 10, 2006¹
• Filings140 in all: 4 (41), 8-K (19), 3 (15), D (13), 4/A (5), 10-Q (4), CORRESP (4), D/A (4)¹
  All 28 form types

  SCHEDULE 13G (4), EFFECT (3), S-1/A (3), SCHEDULE 13G/A (3), UPLOAD (3), 424B5 (2), DRS (2), DRSLTR (2), S-1 (2), 10-K (1), 424B3 (1), 424B4 (1), 8-A12B (1), CERT (1), DEF 14A (1), DRS/A (1), FWP (1), REGDEX (1), S-3 (1), S-8 (1)

• Latest filingsAnnual report (10-K) Mar 26, 2026
  Quarterly report (10-Q) Aug 13, 2026
  Proxy statement (DEF 14A) Apr 28, 2026
  Latest 8-K (8-K) Sep 28, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 26, 2026 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks CapsoVision, Inc names in Item 1A of its 10-K filed Mar 26, 2026: 69 risks under these headings, as written.⁴

• Business and Industry Risk Factors
• We have a history of net losses, and we expect to incur additional losses in the foreseeable future.
• Our audited financial statements for the years ended December 31, 2025 and December 31, 2024 include a footnote raising substantial doubt about our ability to continue as a “going concern” and we will likely need to raise additional financing to fund our business and revenue growth plans.
• All of our revenues to date have been, and in the near-term will continue to be, generated from CapsoCam Plus related sales for the small bowel; and our ability to grow our small-bowel-related revenue is subject to our ability to successfully and timely execute related elements of our revenue growth strategy.
• CapsoCam Colon is our initial strategic effort to expand revenues for our GI-tract capsule endoscopy solution beyond small-bowel-related sales; we do not currently expect to generate CapsoCam Colon-related revenues until FDA clearance for the second generation of our CapsoCam Colon solution.
• Broad adoption of our CapsoCam Colon solution (once cleared) and growing related revenues depend on, among other things, expanding beyond CapsoCam Colon’s initial indicated patient population, increasing the accuracy of our initial CapsoCam Colon solution, and achieving and maintaining a satisfactory successful completion rate for capsule endoscopies using our CapsoCam Colon solution; and we may fail to successfully and timely execute related elements of our CapsoCam Colon adoption and revenue growth strategy.
• Our longer term efforts to expand our GI-tract capsule endoscopy solutions beyond small bowel and colon pathologies and medical conditions may not succeed.
• Any failure or defect in our GI-tract capsule endoscopy solution could harm our reputation, expose us to liability, and reduce our sales.
• We face substantial geopolitical and trade risks (including a possible trade war and imposition of tariffs and supply chain interruptions) and natural disaster risks associated with our business operations in Asia (particularly Taiwan and Japan).
• We may face expansion risks when expanding in existing and entering into new foreign markets.
• The clinical results of our various clinical studies (including those for our CapsoCam Colon capsule) may not be released in any peer-reviewed publications.
• We operate in a highly competitive industry, and competitive pressures could have a material adverse effect on our business, financial condition, results of operations, and prospects.

Legal proceedings

From time to time, we may become involved in various legal proceedings arising from the normal course of business activities. We are not presently a party to any litigation the outcome of which, we believe, if determined adversely to us, would individually or taken together, materially and adversely affect our business, financial condition, or results of operations. Future litigation may be necessary to defend ourselves, our partners, and our customers by determining the scope, enforceability, and validity of third-party proprietary rights, to establish our proprietary rights or for other matters. Involvement in such proceedings is costly and can impose a significant burden on management and employees. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of legal expenses and settlement costs, diversion of management attention, and resources and other factors.

The opening of Item 3, Legal Proceedings.⁴